{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T21:19:23Z","timestamp":1768857563333,"version":"3.49.0"},"reference-count":144,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.lpm.2024.104266","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T17:17:31Z","timestamp":1734023851000},"page":"104266","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment of elderly and frail myeloma patients"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8428-9854","authenticated-orcid":false,"given":"Steven Chun-Min","family":"Shih","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alissa","family":"Visram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hira","family":"Mian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.lpm.2024.104266_bib0001","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.lpm.2024.104266_bib0002","first-page":"513","article-title":"Patient-reported outcomes and assessment of quality of life: a focus on multiple myeloma","volume":"11","author":"Fragola","year":"2020","journal-title":"J Adv Pract Oncol"},{"key":"10.1016\/j.lpm.2024.104266_bib0003","unstructured":"Cancer Stat Facts: myeloma. Surveillance EaERPAoA, 2024 https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"issue":"9","key":"10.1016\/j.lpm.2024.104266_bib0004","doi-asserted-by":"crossref","first-page":"e1406","DOI":"10.1634\/theoncologist.2020-0141","article-title":"Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality, economic resources, and patient empowerment","volume":"25","author":"Ludwig","year":"2020","journal-title":"Oncologist"},{"issue":"24","key":"10.1016\/j.lpm.2024.104266_bib0005","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1200\/JCO.2014.55.1028","article-title":"Multiple myeloma in the older adult: better prospects, more challenges","volume":"32","author":"Wildes","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.lpm.2024.104266_bib0006","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1182\/blood-2005-04-1588","article-title":"Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy","volume":"107","author":"Facon","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.lpm.2024.104266_bib0007","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-020-0311-8","volume":"10","author":"Durie","year":"2020","journal-title":"Blood Cancer J"},{"issue":"Suppl","key":"10.1016\/j.lpm.2024.104266_bib0008","first-page":"14","article-title":"- P09\u2003daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide","volume":"7","author":"K","year":"2023","journal-title":"Hemasphere"},{"issue":"4","key":"10.1016\/j.lpm.2024.104266_bib0009","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jgo.2020.10.009","article-title":"Disparities in treatment patterns and outcomes among younger and older adults with newly diagnosed multiple myeloma: a population-based study","volume":"12","author":"Mian","year":"2021","journal-title":"J Geriatr Oncol"},{"issue":"4","key":"10.1016\/j.lpm.2024.104266_bib0010","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","article-title":"Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States","volume":"1","author":"Costa","year":"2017","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.lpm.2024.104266_bib0011","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.3324\/haematol.2023.282905","article-title":"Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study","volume":"108","author":"McCurdy","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.lpm.2024.104266_bib0012","article-title":"Autologous stem cell transplantation in patients older than 65 years with multiple myeloma: a real-world study","author":"Seehaus","year":"2023","journal-title":"Hematol Transfus Cell Ther"},{"issue":"3","key":"10.1016\/j.lpm.2024.104266_bib0013","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1080\/10428190902741471","article-title":"Diagnostic delay and complications for older adults with multiple myeloma","volume":"50","author":"Friese","year":"2009","journal-title":"Leuke Lympho"},{"issue":"10","key":"10.1016\/j.lpm.2024.104266_bib0014","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/qjmed\/hcm077","article-title":"Multiple myeloma: causes and consequences of delay in diagnosis","volume":"100","author":"Kariyawasan","year":"2007","journal-title":"QJM"},{"key":"10.1016\/j.lpm.2024.104266_bib0015","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.lpm.2024.104266_bib0016","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.lpm.2024.104266_bib0017","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41408-023-00939-y","article-title":"MRD negativity: considerations for older adults with multiple myeloma","volume":"13","author":"Mian","year":"2023","journal-title":"Blood Cancer J"},{"issue":"14","key":"10.1016\/j.lpm.2024.104266_bib0018","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.3390\/cancers15143687","article-title":"Minimal residual disease in multiple myeloma: past, present, and future","volume":"15","author":"Medina-Herrera","year":"2023","journal-title":"Cancers"},{"issue":"23","key":"10.1016\/j.lpm.2024.104266_bib0019","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Advances"},{"issue":"8","key":"10.1016\/j.lpm.2024.104266_bib0020","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.jgo.2020.03.005","article-title":"The characteristics, treatment patterns, and outcomes of older adults aged 80 and over with multiple myeloma","volume":"11","author":"Fiala","year":"2020","journal-title":"J Geriat Oncol"},{"issue":"13","key":"10.1016\/j.lpm.2024.104266_bib0021","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1182\/blood-2009-10-163329","article-title":"How I treat elderly patients with myeloma","volume":"116","author":"Mehta","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2024.104266_bib0022","doi-asserted-by":"crossref","first-page":"215","DOI":"10.14283\/jfa.2019.25","article-title":"Comparison of frailty scores in newly diagnosed patients with multiple myeloma: a review","volume":"8","author":"Mian","year":"2019","journal-title":"J Frailty Aging"},{"issue":"9","key":"10.1016\/j.lpm.2024.104266_bib0023","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1200\/OP.23.00263","article-title":"Practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy: ASCO guideline questions and answers","volume":"19","author":"Williams","year":"2023","journal-title":"JCO Oncol Pract"},{"issue":"13","key":"10.1016\/j.lpm.2024.104266_bib0024","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.lpm.2024.104266_bib0025","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","article-title":"A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial","volume":"34","author":"Facon","year":"2020","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.lpm.2024.104266_bib0026","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/s41375-021-01247-9","article-title":"External validation of the FIRST trial's simplified frailty score in a population-based cohort","volume":"35","author":"Mian","year":"2021","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.lpm.2024.104266_bib0027","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1038\/s41375-020-0712-5","article-title":"Simplified frailty assessment tools: are we really capturing frailty or something else?","volume":"34","author":"Giri","year":"2020","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.lpm.2024.104266_bib0028","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1002\/hem3.85","article-title":"Assessing frailty in myeloma: the pursuit of simplicity may sacrifice precision of predicting clinical outcomes","volume":"8","author":"Groen","year":"2024","journal-title":"Hemasphere"},{"issue":"5","key":"10.1016\/j.lpm.2024.104266_bib0029","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients","volume":"102","author":"Engelhardt","year":"2017","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.lpm.2024.104266_bib0030","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/ajh.24532","article-title":"N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma","volume":"91","author":"Milani","year":"2016","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.lpm.2024.104266_bib0031","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood.2019000758","article-title":"Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies","volume":"134","author":"Liu","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.lpm.2024.104266_bib0032","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1038\/s41375-020-0918-6","article-title":"Defining the vulnerable patient with myeloma\u2014a frailty position paper of the European Myeloma Network","volume":"34","author":"Cook","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.lpm.2024.104266_bib0033","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41408-022-00779-2","article-title":"The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: a systematic review","volume":"13","author":"Mian","year":"2023","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.lpm.2024.104266_bib0034","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41408-023-00843-5","article-title":"Dynamic frailty risk assessment among older adults with multiple myeloma: a population-based cohort study","volume":"13","author":"Mian","year":"2023","journal-title":"Blood Cancer J"},{"issue":"26","key":"10.1016\/j.lpm.2024.104266_bib0035","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.lpm.2024.104266_bib0036","doi-asserted-by":"crossref","first-page":"8017","DOI":"10.1200\/JCO.2016.34.15_suppl.8017","article-title":"Clinical utility of the revised international staging system (RISS) in newly diagnosed multiple myeloma","volume":"34","author":"Tandon","year":"2016","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1016\/j.lpm.2024.104266_bib0037","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: a european myeloma network (EMN) report within the HARMONY project","volume":"40","author":"D'Agostino","year":"2022","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.lpm.2024.104266_bib0038","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1200\/JCO.2012.46.2598","article-title":"Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du my\u00e9lome experience","volume":"31","author":"Avet-Loiseau","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.lpm.2024.104266_bib0039","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s41375-019-0595-5","article-title":"The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial","volume":"34","author":"Pawlyn","year":"2020","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.lpm.2024.104266_bib0040","doi-asserted-by":"crossref","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","article-title":"Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial","volume":"10","author":"Costa","year":"2023","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.lpm.2024.104266_bib0041","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.lpm.2024.104266_bib0042","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1056\/NEJMsa012528","article-title":"Understanding the treatment preferences of seriously ill patients","volume":"346","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.lpm.2024.104266_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2024.101781","article-title":"Understanding health outcome preferences of older adults diagnosed with multiple myeloma","volume":"15","author":"Maheshwari","year":"2024","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.lpm.2024.104266_bib0044","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2147\/PPA.S345906","article-title":"Preferences and priorities for relapsed multiple myeloma treatments among patients and caregivers in the United States","volume":"16","author":"Auclair","year":"2022","journal-title":"Patient Prefer Adherence"},{"issue":"21","key":"10.1016\/j.lpm.2024.104266_bib0045","doi-asserted-by":"crossref","first-page":"5492","DOI":"10.1182\/bloodadvances.2020003044","article-title":"Decisional involvement and information preferences of patients with hematologic malignancies","volume":"4","author":"Loh","year":"2020","journal-title":"Blood Advances"},{"issue":"3","key":"10.1016\/j.lpm.2024.104266_bib0046","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10198-010-0218-6","article-title":"Analysis of physicians' perspectives versus patients' preferences: direct assessment and discrete choice experiments in the therapy of multiple myeloma","volume":"12","author":"M\u00fchlbacher","year":"2011","journal-title":"Eur J Health Econ"},{"issue":"1","key":"10.1016\/j.lpm.2024.104266_bib0047","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1186\/s12885-020-07018-6","article-title":"Alignment of preferences in the treatment of multiple myeloma \u2013 a discrete choice experiment of patient, carer, physician, and nurse preferences","volume":"20","author":"Fifer","year":"2020","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.lpm.2024.104266_bib0048","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1200\/JCO.20.01370","article-title":"Health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma: findings from the phase III MAIA trial","volume":"39","author":"Perrot","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.lpm.2024.104266_bib0049","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00520-023-07902-4","article-title":"Assessment tools for patient-reported outcomes in multiple myeloma","volume":"31","author":"Wang","year":"2023","journal-title":"Support Care Cancer"},{"issue":"9513","key":"10.1016\/j.lpm.2024.104266_bib0050","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"The Lancet"},{"issue":"8","key":"10.1016\/j.lpm.2024.104266_bib0051","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1182\/blood-2008-04-149427","article-title":"Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial","volume":"112","author":"Palumbo","year":"2008","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.lpm.2024.104266_bib0052","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"New Eng J Med"},{"issue":"3","key":"10.1016\/j.lpm.2024.104266_bib0053","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","article-title":"Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma","volume":"131","author":"Facon","year":"2018","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.lpm.2024.104266_bib0054","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1182\/blood.2020009507","article-title":"Dose\/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma","volume":"137","author":"Larocca","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.lpm.2024.104266_bib0055","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/bjh.17350","article-title":"Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group database","volume":"193","author":"Jimenez-Zepeda","year":"2021","journal-title":"Br J Haematol"},{"issue":"10068","key":"10.1016\/j.lpm.2024.104266_bib0056","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.lpm.2024.104266_bib0057","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-020-0311-8","article-title":"Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem","volume":"10","author":"Durie","year":"2020","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.lpm.2024.104266_bib0058","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bjh.15261","article-title":"A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma","volume":"182","author":"O'Donnell","year":"2018","journal-title":"Br J Haematol"},{"issue":"Supplement_1","key":"10.1016\/j.lpm.2024.104266_bib0059","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1182\/blood-2019-128000","article-title":"Updated results of a phase 2 study of modified lenalidomide, bortezomib, and dexamethasone (RVd-lite) in Transplant-ineligible multiple myeloma","volume":"134","author":"O'Donnell","year":"2019","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.lpm.2024.104266_bib0060","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1182\/blood-2019-123401","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in patients with transplant-ineligible newly diagnosed multiple myeloma: overall survival in alcyone","volume":"134","author":"Mateos","year":"2019","journal-title":"Blood"},{"issue":"10218","key":"10.1016\/j.lpm.2024.104266_bib0061","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.lpm.2024.104266_bib0062","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.lpm.2024.104266_bib0063","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"New Eng J Med"},{"issue":"4","key":"10.1016\/j.lpm.2024.104266_bib0064","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.2020010439","article-title":"Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE","volume":"139","author":"San-Miguel","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2024.104266_bib0065","first-page":"P968","article-title":"Final survival analysis of daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Maia study","volume":"421032","author":"Thierry Facon","year":"2024","journal-title":"EHA Library Facon"},{"issue":"4","key":"10.1016\/j.lpm.2024.104266_bib0066","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","article-title":"Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA","volume":"36","author":"Facon","year":"2022","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"10.1016\/j.lpm.2024.104266_bib0067","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1182\/blood-2022-159933","article-title":"A dexamethasone sparing-regimen with daratumumab and lenalidomide in frail patients with newly-diagnosed multiple myeloma: efficacy and safety analysis of the phase 3 IFM2017-03 trial","volume":"140","author":"Manier","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2024.104266_bib0068","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","author":"Facon","year":"2024","journal-title":"N Engl J Med."},{"key":"10.1016\/j.lpm.2024.104266_bib0069","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-024-03050-2","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial","author":"Leleu","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.lpm.2024.104266_bib0070","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","author":"Facon","year":"2024","journal-title":"New Eng J Med"},{"issue":"8","key":"10.1016\/j.lpm.2024.104266_bib0071","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/s41591-024-03050-2","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial","volume":"30","author":"Leleu","year":"2024","journal-title":"Nat Med"},{"issue":"25","key":"10.1016\/j.lpm.2024.104266_bib0072","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1200\/JCO.20.03143","article-title":"Ixazomib, daratumumab, and low-dose dexamethasone in frail patients with newly diagnosed multiple myeloma: the hovon 143 study","volume":"39","author":"Stege","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.lpm.2024.104266_bib0073","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-056147","article-title":"Frailty-adjusted therapy in Transplant Non-Eligible patientswith newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial","volume":"12","author":"Coulson","year":"2022","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.lpm.2024.104266_bib0074","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_432220","article-title":"Tailoring Therapy in Older Adults With Hematologic Malignancies","volume":"44","author":"Mangan","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"9","key":"10.1016\/j.lpm.2024.104266_bib0075","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1634\/theoncologist.2017-0592","article-title":"Representation of minorities and elderly patients in multiple myeloma clinical trials","volume":"23","author":"Duma","year":"2018","journal-title":"Oncologist"},{"issue":"Supplement 1","key":"10.1016\/j.lpm.2024.104266_bib0076","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1182\/blood-2023-189506","article-title":"Comparison of the efficacy in clinical trials versus effectiveness in the real-world of treatments for multiple myeloma: a population-based cohort study","volume":"142","author":"Visram","year":"2023","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.lpm.2024.104266_bib0077","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","article-title":"International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment","volume":"34","author":"Dimopoulos","year":"2016","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.lpm.2024.104266_bib0078","doi-asserted-by":"crossref","first-page":"E612","DOI":"10.1503\/cmaj.221427","article-title":"An approach to treating older adults with chronic kidney disease","volume":"195","author":"Merchant","year":"2023","journal-title":"Canadian Med Assoc J"},{"issue":"23","key":"10.1016\/j.lpm.2024.104266_bib0079","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1200\/JCO.20.00298","article-title":"Randomized trial comparing double versus triple bortezomib-based regimen in patients with multiple myeloma and acute kidney injury due to cast nephropathy","volume":"38","author":"Bridoux","year":"2020","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.lpm.2024.104266_bib0080","doi-asserted-by":"crossref","first-page":"4748","DOI":"10.1182\/blood-2023-188672","article-title":"Dynamic frailty assessment in transplant non-eligible newly diagnosed myeloma patients: initial data from UK myeloma research alliance (UK-MRA) myeloma XIV (FiTNEss): a frailty-adjusted therapy study","volume":"142","author":"Cook","year":"2023","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.lpm.2024.104266_bib0081","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1200\/JCO.2024.42.16_suppl.1625","article-title":"Start low, go slow: a systematic review and meta-analysis of upfront tailored treatment dosing in older adults with advanced cancer","volume":"42","author":"Aleixo","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.lpm.2024.104266_bib0082","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.24793","article-title":"Patient-reported outcome measures in cancer care: an updated systematic review and meta-analysis","volume":"7","author":"Balitsky","year":"2024","journal-title":"JAMA Network Open"},{"issue":"1","key":"10.1016\/j.lpm.2024.104266_bib0083","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1182\/hematology.2023000443","article-title":"A rational approach to functional high-risk myeloma","volume":"2023","author":"Gay","year":"2023","journal-title":"Hematology"},{"issue":"41","key":"10.1016\/j.lpm.2024.104266_bib0084","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1200\/EDBK_320105","article-title":"How to treat high-risk myeloma at diagnosis and relapse","author":"Caro","year":"2021","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"9","key":"10.1016\/j.lpm.2024.104266_bib0085","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.lpm.2024.104266_bib0086","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/leu.2017.211","article-title":"Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65\/GMMG-HD4 trial","volume":"32","author":"Goldschmidt","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.lpm.2024.104266_bib0087","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/leu.2013.335","article-title":"Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients","volume":"28","author":"Nooka","year":"2014","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.lpm.2024.104266_bib0088","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1001\/jamaoncol.2020.4338","article-title":"Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: a Systematic Review and Meta-analysis","volume":"6","author":"Giri","year":"2020","journal-title":"JAMA Oncology"},{"issue":"24","key":"10.1016\/j.lpm.2024.104266_bib0089","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.lpm.2024.104266_bib0090","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.3390\/cancers15102693","article-title":"New strategies for the treatment of older myeloma patients","volume":"15","author":"Larocca","year":"2023","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.lpm.2024.104266_bib0091","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.3390\/life13122259","article-title":"Progression-free survival efficacy in refractory\/relapsed multiple myeloma among elderly patients: a systematic review","volume":"13","author":"Yang","year":"2023","journal-title":"Life"},{"issue":"8","key":"10.1016\/j.lpm.2024.104266_bib0092","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1200\/JCO.22.00940","article-title":"Overall Survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): a randomized, open-label, phase III trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.lpm.2024.104266_bib0093","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1200\/JCO.21.02734","article-title":"Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): a randomized, open-label, phase III trial","volume":"41","author":"Sonneveld","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.lpm.2024.104266_bib0094","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3324\/haematol.2019.217448","article-title":"Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies","volume":"105","author":"Mateos","year":"2020","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.lpm.2024.104266_bib0095","doi-asserted-by":"crossref","first-page":"e813","DOI":"10.1016\/S2352-3026(23)00218-1","article-title":"Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial","volume":"10","author":"Dimopoulos","year":"2023","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.lpm.2024.104266_bib0096","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"34","key":"10.1016\/j.lpm.2024.104266_bib0097","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.2217\/fon-2021-0568","article-title":"Isatuximab for relapsed\/refractory multiple myeloma: review of key subgroup analyses from the phase III ICARIA-MM study","volume":"17","author":"Richardson","year":"2021","journal-title":"Fut Oncol"},{"issue":"11","key":"10.1016\/j.lpm.2024.104266_bib0098","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26319","article-title":"Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed\/refractory multiple myeloma: ICARIA-MM subgroup analysis","volume":"96","author":"Schjesvold","year":"2021","journal-title":"Am J Hematol"},{"issue":"21","key":"10.1016\/j.lpm.2024.104266_bib0099","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1182\/bloodadvances.2020001965","article-title":"Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and\/or refractory multiple myeloma","volume":"4","author":"Facon","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.lpm.2024.104266_bib0100","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hon.3038","article-title":"Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis","volume":"40","author":"Facon","year":"2022","journal-title":"Hematol Oncol"},{"issue":"Suppl","key":"10.1016\/j.lpm.2024.104266_bib0101","article-title":"P907: Carfilzomib, dexamethasone, and daratumumab (KDD) vs carfilzomib and dexamethasone (KD) In relapsed\/refractory multiple myeloma (RRMM): frailty subgroup analysis of the candor study","volume":"6","author":"Quach","year":"2022","journal-title":"Hemasphere"},{"issue":"3","key":"10.1016\/j.lpm.2024.104266_bib0102","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.clml.2023.10.009","article-title":"Pomalidomide, bortezomib, and dexamethasone in lenalidomide-pretreated multiple myeloma: a subanalysis of OPTIMISMM by frailty and bortezomib dose adjustment","volume":"24","author":"Oriol","year":"2024","journal-title":"Clin Lymph Myel Leuk"},{"issue":"1","key":"10.1016\/j.lpm.2024.104266_bib0103","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","article-title":"A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial","volume":"34","author":"Facon","year":"2020","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.lpm.2024.104266_bib0104","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1200\/JCO.21.02815","article-title":"Elotuzumab plus pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.lpm.2024.104266_bib0105","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"New Eng J Med"},{"issue":"4","key":"10.1016\/j.lpm.2024.104266_bib0106","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/ajh.25726","article-title":"Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: a study of the Korean Multiple Myeloma Working Party (KMMWP-164 study)","volume":"95","author":"Lee","year":"2020","journal-title":"Am J Hematol"},{"issue":"17","key":"10.1016\/j.lpm.2024.104266_bib0107","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"New Eng J Med"},{"issue":"6","key":"10.1016\/j.lpm.2024.104266_bib0108","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/ajh.26172","article-title":"Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma","volume":"96","author":"Auner","year":"2021","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.lpm.2024.104266_bib0109","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"New Eng J Med"},{"issue":"10297","key":"10.1016\/j.lpm.2024.104266_bib0110","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.lpm.2024.104266_bib0111","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2023.101628","article-title":"Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: a systematic review and meta-analysis","volume":"15","author":"Akhtar","year":"2024","journal-title":"J Geriatr Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.lpm.2024.104266_bib0112","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-134322","article-title":"Efficacy and safety of idecabtagene vicleucel (ide-cel, bb2121) in elderly patients with relapsed and refractory multiple myeloma: karMMa subgroup analysis","volume":"136","author":"Berdeja","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.lpm.2024.104266_bib0113","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti\u2013B-cell maturation antigen chimeric antigen receptor t-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.lpm.2024.104266_bib0114","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1200\/JCO.2023.41.16_suppl.8009","article-title":"CARTITUDE-1 final results: phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Lin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2 Supplement","key":"10.1016\/j.lpm.2024.104266_bib0115","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1016\/j.jtct.2023.12.239","article-title":"Real world outcomes of older adults and frail patients with relapse\/refractory multiple myeloma receiving idecabtagene vicleucel","volume":"30","author":"Akhtar","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.lpm.2024.104266_bib0116","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.14213","article-title":"Multiple myeloma: patient outcomes in real-world practice","volume":"175","author":"Yong","year":"2016","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.lpm.2024.104266_bib0117","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"New Eng J Med"},{"issue":"11","key":"10.1016\/j.lpm.2024.104266_bib0118","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.lpm.2024.104266_bib0119","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.lpm.2024.104266_bib0120","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nature Medicine"},{"issue":"24","key":"10.1016\/j.lpm.2024.104266_bib0121","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.lpm.2024.104266_bib0122","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1158\/2643-3230.BCD-21-0028","article-title":"Bispecific antibodies in multiple myeloma: present and future","volume":"2","author":"Lancman","year":"2021","journal-title":"Blood Cancer Discovery"},{"issue":"2","key":"10.1016\/j.lpm.2024.104266_bib0123","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.hoc.2023.12.004","article-title":"Chimeric antigen receptor t cells in the treatment of multiple myeloma","volume":"38","author":"Hasanali","year":"2024","journal-title":"Hematol Oncol Clin North Am"},{"issue":"11","key":"10.1016\/j.lpm.2024.104266_bib0124","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.lpm.2024.104266_bib0125","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2023-180458","article-title":"Toxicity and efficacy outcomes of teclistamab in patients with relapsed-refractory multiple myeloma (RRMM) above the age of 70 years: a multicenter study","volume":"142","author":"Dima","year":"2023","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.lpm.2024.104266_bib0126","doi-asserted-by":"crossref","first-page":"8040","DOI":"10.1200\/JCO.2023.41.16_suppl.8040","article-title":"Efficacy and safety of elranatamab by age and frailty in patients (pts) with relapsed\/refractory multiple (RRMM): a subgroup analysis from MagnetisMM-3","volume":"41","author":"Raje","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2024.104266_bib0127","doi-asserted-by":"crossref","first-page":"S406","DOI":"10.1016\/j.htct.2023.09.767","article-title":"Efficacy and safety of elranatamab by age and frailty in patients with relapsed\/refractory multiple myeloma: a subgroup analysis from magnetismm-3","volume":"45","author":"Raje","year":"2023","journal-title":"Hematol Transfus Cell Ther"},{"issue":"16_suppl","key":"10.1016\/j.lpm.2024.104266_bib0128","doi-asserted-by":"crossref","first-page":"8036","DOI":"10.1200\/JCO.2023.41.16_suppl.8036","article-title":"Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Schinke","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.lpm.2024.104266_bib0129","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood-2023-187242","article-title":"Updated results of talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma with prior exposure to t-cell redirecting therapies: results of the phase 1\/2 monumental-1 study","volume":"142","author":"Jakubowiak","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.lpm.2024.104266_bib0130","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.lpm.2024.104266_bib0131","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108078","article-title":"Diabetes and global ageing among 65-99-year-old adults: findings from the International Diabetes Federation Diabetes Atlas, 9(th) edition","volume":"162","author":"Sinclair","year":"2020","journal-title":"Diabetes Res Clin Pract."},{"issue":"7","key":"10.1016\/j.lpm.2024.104266_bib0132","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.3324\/haematol.2020.267757","article-title":"Symptom burden in transplant-ineligible patients with newly diagnosed multiple myeloma: a population-based cohort study","volume":"106","author":"Mian","year":"2021","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.lpm.2024.104266_bib0133","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/ajh.25797","article-title":"Transplant eligibility in elderly multiple myeloma patients: prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75\u2009years","volume":"95","author":"Belotti","year":"2020","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.lpm.2024.104266_bib0134","doi-asserted-by":"crossref","first-page":"e628","DOI":"10.1016\/S2666-7568(22)00172-6","article-title":"Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA, multicentre, cross-sectional study","volume":"3","author":"Efficace","year":"2022","journal-title":"Lancet Health Longev"},{"issue":"7","key":"10.1016\/j.lpm.2024.104266_bib0135","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1038\/s41375-020-0713-4","article-title":"Validation of the FIRST simplified frailty scale using the ECOG performance status instead of patient-reported activities","volume":"34","author":"Stege","year":"2020","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.lpm.2024.104266_bib0136","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/s41375-021-01247-9","article-title":"External validation of the FIRST trial's simplified frailty score in a population-based cohort","volume":"35","author":"Mian","year":"2021","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.lpm.2024.104266_bib0137","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients","volume":"102","author":"Monika","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.lpm.2024.104266_bib0138","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2019-127030","volume":"134","author":"Schoeller","year":"2019","journal-title":"Blood"},{"issue":"10068","key":"10.1016\/j.lpm.2024.104266_bib0139","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.lpm.2024.104266_bib0140","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/bloodadvances.2023010026","article-title":"Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study","volume":"7","author":"Usmani","year":"2023","journal-title":"Blood Advances"},{"issue":"22","key":"10.1016\/j.lpm.2024.104266_bib0141","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1200\/JCO.21.00972","article-title":"Final overall survival analysis of the TOURMALINE-MM1 phase III trial of ixazomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"39","author":"Richardson","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.lpm.2024.104266_bib0142","article-title":"P879: long-term follow-up from majestec-1 of teclistamab, a b-cell maturation antigen (BCMA) x cd3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"7","author":"Sidana","year":"2023","journal-title":"Hemasphere"},{"issue":"7","key":"10.1016\/j.lpm.2024.104266_bib0143","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.136","article-title":"Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: update from the MagnetisMM-3 study","volume":"8","author":"Tomasson","year":"2024","journal-title":"HemaSphere"},{"issue":"Suppl","key":"10.1016\/j.lpm.2024.104266_bib0144","article-title":"P29\u2003phase 1\/2 results of talquetamab, a g protein-coupled receptor family c group 5 member d x cd3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM) (MONUMENTAL-1)","volume":"7","author":"Minnema","year":"2023","journal-title":"Hemasphere"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498224000459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498224000459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T23:46:53Z","timestamp":1741045613000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498224000459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":144,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0755498224000459"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2024.104266","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of elderly and frail myeloma patients","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2024.104266","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"104266"}}